Global Erectile Dysfunction Market Growth 2023-2029

Global Erectile Dysfunction Market Growth 2023-2029

Erectile dysfunction (ED), also known as impotence, is a type of sexual dysfunction characterized by the inability to develop or maintain an erection of the penis during sexual activity. Erectile dysfunction can have psychological consequences as it can be tied to relationship difficulties and self-image.

LPI (LP Information)' newest research report, the “Erectile Dysfunction Industry Forecast” looks at past sales and reviews total world Erectile Dysfunction sales in 2022, providing a comprehensive analysis by region and market sector of projected Erectile Dysfunction sales for 2023 through 2029. With Erectile Dysfunction sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Erectile Dysfunction industry.

This Insight Report provides a comprehensive analysis of the global Erectile Dysfunction landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Erectile Dysfunction portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Erectile Dysfunction market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Erectile Dysfunction and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Erectile Dysfunction.

The global Erectile Dysfunction market size is projected to grow from US$ 4758.1 million in 2022 to US$ 7793.2 million in 2029; it is expected to grow at a CAGR of 7793.2 from 2023 to 2029.

Eli Lilly is one of the most important global key manufacturers of erectile dysfunction, holds a share of about 10%, other key players include Teva Pharma and Pfizer, etc. North America is the largest market, occupied for over 40 percent, followed by Europe. In terms of type, tadalafil type is the largest segment, with a share of over 50%, and in terms of sales channels, the hospital pharmacies segment holds a share of over 30 percent.

This report presents a comprehensive overview, market shares, and growth opportunities of Erectile Dysfunction market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Sildenafil
Tadalafil
Others

Segmentation by application
Hospital Pharmacies
Private Clinics
Retail Pharmacies
E-Commerce (B2B)
E-Commerce (B2C)

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Eli Lilly
Pfizer
Bayer
BaiYunShan General Factory
S.K. Chemicals
Teva Pharma
Dong-A ST
Petros Pharmaceuticals
Seoul Pharma
Yabang Pharmacy

Key Questions Addressed in this Report

What is the 10-year outlook for the global Erectile Dysfunction market?

What factors are driving Erectile Dysfunction market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Erectile Dysfunction market opportunities vary by end market size?

How does Erectile Dysfunction break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.